Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed AML

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01664897
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:27.529415+00:00
Published At
2020-01-07T00:00:00+00:00
Record Updated At
2020-01-07
Results Posted At
2020-01-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A", "Adult Acute Promyelocytic Leukemia With PML-RARA", "Alkylating Agent-Related Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-01-07"
protocolSection.identificationModule.nctId
"NCT01664897"
protocolSection.identificationModule.officialTitle
"A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed AML"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-01-07"

Study condition terms

  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A (protocolSection.conditionsModule.conditions)
  • Adult Acute Promyelocytic Leukemia With PML-RARA (protocolSection.conditionsModule.conditions)
  • Alkylating Agent-Related Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Previously Treated Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.